Year All20242023202220212020201920182017201620152014 Abivax Establishes an At-the-Market (ATM) Program on Nasdaq November 19, 2024 Read More Abivax presents third quarter 2024 key financial information November 14, 2024 Read More Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax November 13, 2024 Read More Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation October 07, 2024 Read More Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease October 03, 2024 Read More Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance October 03, 2024 Read More Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 September 26, 2024 Read More Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model September 25, 2024 Read More Abivax presents first-half 2024 financial results September 09, 2024 Read More Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone August 06, 2024 Read More
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax November 13, 2024 Read More
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation October 07, 2024 Read More
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease October 03, 2024 Read More
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance October 03, 2024 Read More
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 September 26, 2024 Read More
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model September 25, 2024 Read More
